- Supports functional safety - Developed in compliant with ISO 26262 2nd edition - Safety manual and safety analysis reports - Built-in functional redundancy, ... Final sample offering January 2022 ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial. Updates include positive functional, safety and biomarker data for RGX-202 ...

Updates include positive functional, safety and biomarker data for RGX-202, REGENXBIO's potential best-in-class, investigational gene therapy for Duchenne muscular dystrophy. At the same dose ...